SiTime Corporation R&D increased by 15.7% to $32.74M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.0%, from $30.03M to $32.74M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 22.9% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.07M | $13.01M | $15.85M | $20.60M | $22.02M | $23.88M | $23.80M | $24.46M | $26.57M | $23.65M | $22.92M | $25.54M | $25.49M | $26.49M | $29.33M | $30.03M | $30.56M | $30.01M | $28.30M | $32.74M |
| QoQ Change | — | +7.8% | +21.9% | +29.9% | +6.9% | +8.5% | -0.3% | +2.8% | +8.6% | -11.0% | -3.1% | +11.5% | -0.2% | +3.9% | +10.7% | +2.4% | +1.8% | -1.8% | -5.7% | +15.7% |
| YoY Change | — | — | — | — | +82.5% | +83.6% | +50.1% | +18.8% | +20.7% | -1.0% | -3.7% | +4.4% | -4.1% | +12.0% | +28.0% | +17.5% | +19.9% | +13.3% | -3.5% | +9.0% |